ENTA · Enanta Pharmaceuticals Inc · Earnings Call Transcripts & Audio
Market Cap
$377.47M
Shares
29.13M
Enanta Pharmaceuticals Inc Earnings Call Transcripts
Quarterly earnings calls for Enanta Pharmaceuticals Inc (ENTA), with available speaker-labelled transcripts, captured audio replays, call highlights, 8-K earnings releases and periodic filings. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▼39.6%
$31.74M
−$8.33M
'21 Q1
21-02-08
▼27.1%
$20.13M
−$22.05M
'21 Q2
21-05-06
▲15.9%
$21.62M
−$24.02M
'21 Q3
21-08-05
▼0.2%
$23.57M
−$24.60M
'21 Q4
21-11-22
▼12.9%
$27.65M
−$30.11M
'22 Q1
22-02-08
▼7%
$18.72M
−$33.59M
'22 Q2
22-05-09
▼9.9%
$19.48M
−$31.70M
'22 Q3
22-08-08
▼13.8%
$20.32M
−$26.35M
'22 Q4
22-11-21
▼14.7%
$23.59M
−$28.99M
'23 Q1
23-02-07
▼4.9%
$17.80M
−$37.66M
'23 Q2
23-05-08
▼3%
$18.89M
−$39.06M
'23 Q3
23-08-07
▼6.8%
$18.93M
−$28.11M
'23 Q4
23-11-20
▼23.7%
$18.00M
−$33.41M
'24 Q1
24-02-07
▼4.2%
$17.05M
−$31.16M
'24 Q2
24-05-06
▼4.9%
$17.97M
−$22.66M
'24 Q3
24-08-05
LATEST
▼22.8%
$14.61M
−$28.82M
'24 Q4
24-11-25
Conference
Investor event
2026-09-16
Enanta Pharmaceuticals Inc (ENTA) September 2026 Conference
Scheduled
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-09-15
Enanta Pharmaceuticals Inc (ENTA) September 2026 Conference
Scheduled
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-06-04
Enanta Pharmaceuticals Inc (ENTA) June 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY24 · Q4
2024-11-25
Enanta Pharmaceuticals Inc (ENTA) Q4 2024 Earnings Call
Revenue
$14.61M*
▼ 22.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-08-05
Enanta Pharmaceuticals Inc (ENTA) Q3 2024 Earnings Call
Revenue
$17.97M
▼ 4.9% YoY Diluted EPS
$-1.07
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-05-06
Enanta Pharmaceuticals Inc (ENTA) Q2 2024 Earnings Call Transcript
Balanced tone
RSV pipeline (zelicapavir/EDP-938 and EDP-323)
Immunology / CSU oral KIT inhibitor program
Pfizer patent litigation
Revenue
$17.05M
▼ 4.2% YoY Diluted EPS
$-1.47
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-02-07
Enanta Pharmaceuticals Inc (ENTA) Q1 2024 Earnings Call Transcript
Positive tone
RSV program - zelicapavir (N-protein inhibitor)
Immunology/CSU program
RSV program - EDP-323 (L-protein inhibitor)
Revenue
$18.00M
▼ 23.7% YoY Diluted EPS
$-1.58
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2023-11-20
Enanta Pharmaceuticals Inc (ENTA) Q4 2023 Earnings Call Transcript
Revenue
$18.93M*
▼ 6.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-08-07
Enanta Pharmaceuticals Inc (ENTA) Q3 2023 Earnings Call Transcript
Revenue
$18.89M
▼ 3% YoY Diluted EPS
$-1.86
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-05-08
Enanta Pharmaceuticals Inc (ENTA) Q2 2023 Earnings Call Transcript
Revenue
$17.80M
▼ 4.9% YoY Diluted EPS
$-1.79
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-02-07
Enanta Pharmaceuticals Inc (ENTA) Q1 2023 Earnings Call Transcript
Revenue
$23.59M
▼ 14.7% YoY Diluted EPS
$-1.39
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2022-11-21
Enanta Pharmaceuticals Inc (ENTA) Q4 2022 Earnings Call Transcript
Revenue
$20.32M*
▼ 13.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-08-08
Enanta Pharmaceuticals Inc (ENTA) Q3 2022 Earnings Call Transcript
Revenue
$19.48M
▼ 9.9% YoY Diluted EPS
$-1.53
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-05-09
Enanta Pharmaceuticals Inc (ENTA) Q2 2022 Earnings Call Transcript
Revenue
$18.72M
▼ 7% YoY Diluted EPS
$-1.63
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-02-08
Enanta Pharmaceuticals Inc (ENTA) Q1 2022 Earnings Call Transcript
Revenue
$27.65M
▼ 12.9% YoY Diluted EPS
$-1.48
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2021-11-22
Enanta Pharmaceuticals Inc (ENTA) Q4 2021 Earnings Call Transcript
Revenue
$23.57M*
▼ 0.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-08-05
Enanta Pharmaceuticals Inc (ENTA) Q3 2021 Earnings Call Transcript
Revenue
$21.62M
▲ 15.9% YoY Diluted EPS
$-1.19
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-05-06
Enanta Pharmaceuticals Inc (ENTA) Q2 2021 Earnings Call Transcript
Revenue
$20.13M
▼ 27.1% YoY Diluted EPS
$-1.09
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-02-08
Enanta Pharmaceuticals Inc (ENTA) Q1 2021 Earnings Call Transcript
Revenue
$31.74M
▼ 39.6% YoY Diluted EPS
$-0.41
▼ 163.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2020-11-23
Enanta Pharmaceuticals Inc (ENTA) Q4 2020 Earnings Call Transcript
Revenue
$23.63M
▼ 53.9% YoY Diluted EPS
$-1.46
▼ 431.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-08-04
Enanta Pharmaceuticals Inc (ENTA) Q3 2020 Earnings Call Transcript
Revenue
$18.65M
▼ 58% YoY Diluted EPS
$-0.71
▼ 315.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-05-06
Enanta Pharmaceuticals Inc (ENTA) Q2 2020 Earnings Call Transcript
Revenue
$27.62M
▼ 30.3% YoY Diluted EPS
$-0.30
▼ 250% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-02-06
Enanta Pharmaceuticals Inc (ENTA) Q1 2020 Earnings Call Transcript
Revenue
$52.57M
▼ 24.8% YoY Diluted EPS
$0.65
▼ 48% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Showing 1–23 of 23 earnings calls
Key facts
CIK
1177648
CUSIP
29251M106
13F (30d)
40 filings
40 filers
Visit website
Investor relations